Document is current

Article History

Received: 12 October 2024

Accepted: 3 April 2025

First Online: 27 May 2025

Declarations

:

: All the authors declare no conflict of interest in relation to this manuscript. Outside this scope, Dr Rahman, Dr Rao, Dr Garcia, and Dr Ioannidis worked as a consultant and speaker for Allergan Aesthetics, an Abbvie company (Irvine, CA); Karim Sayed is a consultant to, speaker for, and has received honoraria from L’oréal/Skinceuticals, Teoxane, Lutronic, Cynosure, and Allergan, an AbbVie Company (Irvine, CA); Dr Philipp-Dormston reports being a clinical trial investigator, scientific advisor, and/or speaker for Allergan Aesthetics an Abbvie company (Irvine, CA), Galderma (Lausanne, Switzerland), Merz Pharmaceuticals GmbH, and Evolus. He is also Senior President of the German Society for Botulinum and Filler Treatment (DGBT); Dr Almeida has been a consultant to Allergan Inc. and Merz and participated in clinical trials for Allergan and Galderma; Dr Wu is a speaker and consultant for Allergan Aesthetics an Abbvie Company, Merz Pharmaceuticals GmbH; Dr Goodman is a speaker, investigator, and consultant for Allergan Aesthetics an Abbvie Company (Irvine, Calif.) and Galderma (Lausanne, Switzerland). He is the President of Australian Society of Cosmetic Dermatologists; Dr J Carruthers has been a consultant and researcher for Alastin, Appiell, Allergan Aesthetics, an AbbVie Company, Avari, Bonti (now with Allergan/AbbVie), Evolus, Fount Bio, In Mode, Jeune Aesthetics, Merz, and Revance Biopharma and also own shares in Galderma. She is an author and editor for Elsevier and “Up to Date” Neuromodulators and Fillers, as well as an assistant editor for Dermatologic Surgery; Dr Sadeghi-Esfahlani, Dr Yu, and Dr Webb have nothing to disclose.

: This article contains no studies with human participants or animals performed by any of the authors. For this type of study, informed consent is not required.